Last reviewed · How we verify
GSK3359609
At a glance
| Generic name | GSK3359609 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM (PHASE1, PHASE2)
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) (PHASE1)
- Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE3)
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors (PHASE1)
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (PHASE1, PHASE2)
- Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK3359609 CI brief — competitive landscape report
- GSK3359609 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI